France's Sanofi to supply bird flu vaccine to US

16th September 2005, Comments 0 comments

PARIS, Sept 15 (AFP) - Sanofi Pasteur, a subsidiary of French pharmaceutical group Sanofi-Aventis, said on Thursday that it had won a contract worth US $100 million (EUR 82 million) to supply a bird flu vaccine to the United States.

PARIS, Sept 15 (AFP) - Sanofi Pasteur, a subsidiary of French pharmaceutical group Sanofi-Aventis, said on Thursday that it had won a contract worth US $100 million (EUR 82 million) to supply a bird flu vaccine to the United States.

A statement from the French group said the US Department of Health and Human Services had ordered the production of a concentrated form of the vaccine in bulk, which would be manufactured in the next two months.

The group said in August that it was working on the production of a prototype vaccine for humans to combat H5N1, the virus strain widely thought to be the cause of bird flu.

This much-larger contract followed a similar deal in September 2004 when Sanofi won a 13-million-dollar deal with the US government to produce two million doses of an anti-bird flu vaccine.

Further payments would be made to the French company for vaccine storage and conditioning upon request from the US government, Sanofi said.

Production of the vaccine would take place at Sanofi Pasteur's US headquarters in Swiftwater, Pennsylvania.

The company said that 68 cases of human bird flu contaminations had been reported to the World Health Organisation between December 16, 2005 and August 5.

Copyright AFP

Subject: French news

0 Comments To This Article